Form 4: Corcept Therapeutics Director Exercises Options and Sells Shares

Director Daniel N. Swisher Jr. exercised stock options and sold shares of Corcept Therapeutics on January 10, 2025, according to a recent SEC filing.

Summary

• On January 10, 2025, Daniel N. Swisher Jr., a director at Corcept Therapeutics, exercised stock options to acquire 2,200 shares of common stock at a price of $12.13 per share.
• Following the exercise of these options, Mr. Swisher sold 2,200 shares of common stock at a price of $50.54 per share.
• After these transactions, Mr. Swisher directly owns 0 shares of common stock and 8,400 stock options.

Sentiment

Score: 5

Explanation: The document is neutral in sentiment as it reports a routine insider transaction. The sale of shares could be seen as slightly negative, but the pre-planned nature mitigates this.

Positives

• The exercise of options at $12.13 and subsequent sale at $50.54 indicates a significant profit for the director.
• The use of a 10b5-1 plan suggests a pre-planned and transparent approach to trading.

Negatives

• The sale of 2,200 shares by a director could be interpreted as a lack of confidence in the company's future performance, although this is mitigated by the pre-planned nature of the sale.

Risks

• Insider transactions, even when pre-planned, can sometimes create uncertainty among investors.
• The market may react negatively to the sale of shares by a director, even if it is part of a pre-arranged plan.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common in publicly traded companies. It provides transparency into the transactions of company directors and officers.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among corporate insiders to avoid accusations of illegal insider trading.
• The reported transactions are typical for directors who hold stock options and periodically exercise and sell shares for personal financial management.
• Similar filings are regularly made by directors and officers of other publicly traded companies such as Pfizer, Moderna, and Regeneron.

Stakeholder Impact

• Shareholders may react to the director's sale of shares, although the pre-planned nature of the transaction should reduce any negative impact.
• The transaction has no direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Corcept Therapeutics, insider trading, stock options, SEC Form 4, 10b5-1 plan, director, equity securities, CORT